Compound mutations involving T315I and P-loop mutations are the major components of multiple mutations detected in tyrosine kinase inhibitor resistant chronic myeloid leukemia-Reference-Cited by-同舟云学术

Compound mutations involving T315I and P-loop mutations are the major components of multiple mutations detected in tyrosine kinase inhibitor resistant chronic myeloid leukemia

Published:2019-01 Issue: Volume:76 Page:87-93
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Kang Ki-Hoon,Kim Soo-Hyun,Choi Soo-Young,Yoo Hae-Lyun,Lee Mi-Young,Song Hye-Young,Kee Kyung-Mi,Suh Ji-Hyung,Yang Seon-Young,Jang Eun-Jung,Lee Sung-Eun^ORCID,Kim Dong-Wook

Funder

Korea Leukemia Bank

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference35 articles.

1. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification;Gorre;Science (New York, N.Y.),2001

2. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study;von Bubnoff;Lancet (Lond., Engl.),2002

3. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis;Branford;Blood,2003

4. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase;Hughes;J. Clin. Oncol.,2009

5. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations;Muller;Blood,2009

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia;International Journal of Biological Sciences;2024

2. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia;Leukemia;2023-10-04

3. Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor;European Journal of Medicinal Chemistry;2022-12

4. New treatment strategies for advanced-stage gastrointestinal stromal tumours;Nature Reviews Clinical Oncology;2022-02-25

5. Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review;World Journal of Clinical Oncology;2021-02-24